Key Highlights
- About 22% was the gain for IDEXX Laboratories (NASDAQ:IDXX) on November 2, 2026, closing near USD 671.64 after third-quarter results.
- USD 1.214 billion of third-quarter revenue, up 10%, against about USD 1.19 billion expected, with diluted Earnings of USD 4.01 a share against USD 3.40.
- USD 14.96 to USD 15.16 is the new 2026 earnings guidance, up from USD 14.69 to USD 14.94, with Revenue guided to USD 4.741 billion to USD 4.767 billion.
- 33.1% operating margin, up from 32.1%, while the full-year margin range of 32.1% to 32.3% is below the 32.3% to 32.5% given in August.
What IDEXX Reported
IDEXX reported third-quarter 2026 results on November 2, 2026. Revenue rose 10% to about USD 1.214 billion and diluted earnings rose 18% to USD 4.01 a share, above the published consensus of USD 3.71. Operating Margin was 33.1%. Recurring diagnostics revenue in its companion animal group was USD 967 million, up 11%, led by a 14% rise in consumables for its in-clinic analyzers. The company placed 5,780 premium instruments, including 1,904 of its inVue Dx analyzers. The shares closed up about 22% at USD 671.64, one of the largest gains in the S&P 500 that day, according to published market data. Recurring diagnostics growth is the number investors prize because it repeats each quarter, and the premium instrument placements feed it. Organic revenue growth guidance was lifted to 9.3% to 10.0% from 8.5% to 9.7%, a sign that the beat was not only currency.
What Is in the Guidance
IDEXX raised its 2026 outlook for revenue to USD 4.741 billion to USD 4.767 billion, organic growth to 9.3% to 10.0% and earnings to USD 14.96 to USD 15.16. The operating margin range of 32.1% to 32.3% is lower than the 32.3% to 32.5% given in the second quarter, so the earnings raise came from items below operating profit, such as tax and interest. One analysis attributes the raise to a lower tax rate, lower interest expense and fewer shares, and links the margin cut to costs from its CoVet software deal. The Business follows a razor-and-blade model: each analyzer placed generates years of consumable sales. Earnings guidance rose by about USD 0.25 at the low end and USD 0.22 at the high end (simple arithmetic), so IDEXX Laboratories (NASDAQ:IDXX) has narrowed its outlook while lifting it.
Risks and What to Watch Next
The same published analysis notes that same-store clinical visits fell 1.8% and rapid assay testing volumes declined, with price alone keeping those sales growing. If veterinary visits stay soft, Volume growth could slow. Margin guidance implies little improvement in the fourth quarter. After a 22% one-day rise, expectations are high, and moves of that size can reverse. Investors will watch visit trends, instrument placements, consumable growth, the cost of software integration and whether the company can hold margins in the fourth quarter. The seventh straight quarterly earnings beat, noted in published coverage, also sets a high bar, because a miss against a long run of beats tends to be punished.
Where Things Stand
IDEXX jumped about 22% because it beat on revenue and earnings, raised revenue and earnings guidance and showed Recurring Revenue growth of 11%. The gains are not all operational: the earnings raise leans on tax, interest and share count, and the margin outlook was lowered. For IDEXX Laboratories (NASDAQ:IDXX), visit trends and fourth-quarter margins are the next tests. A 22% day can partly reverse. Nothing here is Investment advice or a price forecast.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...